Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction

Diabetes Care

Volumn 37, Issue 11, 2014, Pages 3003-3008

  Lindberg, Soren ^a   Jensen, Jan S ^a,b   Pedersen, Sune H ^a   Galatius, Soen ^a   Frystyk, Jan ^c   Flyvbjerg, Allan ^c   Bjerre, Mette ^c   Mogelvang, Rasmus ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ANTILIPEMIC AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CHOLESTEROL; CLOPIDOGREL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TROPONIN I; GLUCOSE BLOOD LEVEL; INSULIN;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY CARE UNIT; DISEASE ASSOCIATION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TERTIARY CARE CENTER; ADIPOSE TISSUE; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; FOLLOW UP; HEART INFARCTION; INCIDENCE; METABOLISM; MIDDLE AGED; RISK FACTOR; SECRETION (PROCESS); VERY ELDERLY;

ADIPONECTIN; ADIPOSE TISSUE; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INSULIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84910123008     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0932     Document Type: Article

References (31)

1. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-1792
2. Saltevo J, Laakso M, Jokelainen J, Keinäanen-Kiukaanniemi S, Kumpusalo E, Vanhala M. Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with insulin sensitivity: a population-based study. Diabetes Metab Res Rev 2008;24:378-383
3. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Löowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol 2006;48:1369-1377
4. Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 2007;30:1200-1205
5. Tabák AG, Brunner EJ, Miller MA, et al. Low serum adiponectin predicts 10-year risk of type 2 diabetes and HbA1c independently of obesity, lipids, and inflammation: Whitehall II study. Horm Metab Res 2009;41:626-629
6. Heidemann C, Sun Q, van DamRM, et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 2008;149:307-316
7. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-2144
8. Norhammar AM, Rydén L, Malmberg K. Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care 1999;22:1827-1831
9. Wallander M, Bartnik M, Efendic S, et al. Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. Diabetologia 2005;48:2229-2235
10. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008;14:741-751
11. Lee YH, Magkos F, Mantzoros CS, Kang ES. Effects of leptin and adiponectin on pancreatic β-cell function. Metabolism 2011;60:1664-1672
12. Lindberg S, Pedersen SH, Mogelvang R, et al. Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2012;109:492-496
13. Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005;48:1911-1918
14. Andersen KK, Frystyk J, Wolthers OD, Heuck C, Flyvbjerg A. Gender differences of oligomers and total adiponectin during puberty: a cross-sectional study of 859 Danish school children. J Clin Endocrinol Metab 2007;92:1857-1862
15. Vervoort G, Klein Gunnewiek JM, Willems HL, Wetzels JF. Effect of creatinine assay standardization on the performance of Cockcroft-Gault and MDRD formula in predicting GFR. Nephrol Dial Transplant 2006;21:2998-2999
16. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509
17. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8:551-561
18. Tabák AG, Carstensen M, Witte DR, et al. Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study. Diabetes Care 2012;35:2540-2547
19. Lindberg S, Jensen JS, Bjerre M, et al. Adiponectin, type 2 diabetes and cardiovascular risk. Eur J Prev Cardiol. 25 November 2013 [Epub ahead of print]
20. Oswald GA, Smith CC, Betteridge DJ, Yudkin JS. Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction. Br Med J (Clin Res Ed) 1986;293:917-922
21. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-240
22. Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009;53:2070-2077
23. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD; Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004;110:3206-3212
24. Wannamethee SG, Welsh P, Whincup PH, et al. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association? Eur J Cardiovasc Prev Rehabil 2011;18:65-71
25. Lindberg S, Jensen JS, Bjerre M, et al. Cardio-adipose tissue cross-talk: relationship between adiponectin, plasma pro brain natriuretic peptide and incident heart failure. Eur J Heart Fail 2014;16:633-638
26. Riezebos RK, Ronner E, de Boer BA, Slaats EH, Tijssen JG, Laarman GJ. Dynamics in Nterminal pro-brain natriuretic peptide concentration in patients with non-ST-elevation acute coronary syndrome. Am Heart J 2005;150:1255-1259
27. Souza SC, Chau MD, Yang Q, et al. Atrial natriuretic peptide regulates lipid mobilization and oxygen consumption in human adipocytes by activating AMPK. Biochem Biophys Res Commun 2011;410:398-403
28. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007;115:1345-1353
29. Magnusson M, Jujic A, Hedblad B, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab 2012;97:638-645
30. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93(Suppl. 1):S64-S73
31. Kizer JR, Arnold AM, Benkeser D, et al. Total and high-molecular-weight adiponectin and risk of incident diabetes in older people. Diabetes Care 2012;35:415-423